EP4059923A1 — 4-oxoquinoline compound and use thereof as hiv integrase inhibitor
Assigned to Japan Tobacco Inc · Expires 2022-09-21 · 4y expired
What this patent protects
An anti-HIV agent containing, as an active ingredient, a 4-oxoquinoline compound represented by the following formulawherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof. The compound of the present invention has HIV integrase inhi…
USPTO Abstract
An anti-HIV agent containing, as an active ingredient, a 4-oxoquinoline compound represented by the following formulawherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof. The compound of the present invention has HIV integrase inhibitory action and is useful as an anti-HIV agent for the prophylaxis or therapy of AIDS. Moreover, by a combined use with other anti-HIV agents such as protease inhibitors, reverse transcriptase inhibitors and the like, the compound can become a more effective anti-HIV agent. Since the compound has high inhibitory activity specific for integrases, it can provide a safe pharmaceutical agent with a fewer side effects for human.
Drugs covered by this patent
- Tybost (COBICISTAT) · Gilead Sciences
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.